Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive,

Định dạng: pdf / Số trang: 12

Nhắn tin với admin nếu không tải được